|1.||Pollock, Pamela M: 3 articles (11/2012 - 09/2008)|
|2.||Byron, Sara A: 3 articles (11/2012 - 09/2008)|
|3.||Sodani, Kamlesh: 2 articles (06/2014 - 07/2013)|
|4.||Anreddy, Nagaraju: 2 articles (06/2014 - 07/2013)|
|5.||Chen, Zhe-Sheng: 2 articles (06/2014 - 07/2013)|
|6.||Patel, Atish: 2 articles (06/2014 - 07/2013)|
|7.||Sweeny, Larissa: 2 articles (07/2012 - 08/2011)|
|8.||Liu, Zhiyong: 2 articles (07/2012 - 08/2011)|
|9.||Rosenthal, Eben L: 2 articles (07/2012 - 08/2011)|
|10.||Hartman, Yolanda E: 2 articles (07/2012 - 08/2011)|
02/01/2014 - "Importantly, we found that FGFR inhibition by PD173074 reduced myeloid-derived suppressor cells (MDSCs) in the blood, spleens and tumors, accompanied by the increased infiltration of CD4(+) and CD8(+) T cells in the spleens and tumors. "
02/01/2014 - "Meanwhile, PD173074 functionally reduced microvessel density and proliferation index and induced tumor apoptosis. "
02/01/2014 - "In 4T1 tumor-bearing mice, PD173074 significantly inhibited tumor growth without obvious side effects. "
07/01/2013 - "PD173074, a selective FGFR inhibitor, reverses ABCB1-mediated drug resistance in cancer cells."
07/01/2012 - "Additionally, those tumors from mice treated with PD173074 had a smaller stromal component, decreased proliferation, and increased apoptosis. "
|2.||Breast Neoplasms (Breast Cancer)
08/15/2011 - "TN breast cancer cell lines were more sensitive to PD173074 than comparator cell lines (P = 0.011), with 47% (7/15) of TN cell lines showing significantly reduced growth. "
08/15/2011 - "We examined the sensitivity of a panel of 31 breast cancer cell lines to the selective FGFR inhibitor PD173074 and investigated the potential mechanisms underlying sensitivity. "
09/15/2007 - "TC-1 was down regulated by the FGFR inhibitor PD173074 in the breast cancer cell line SUM-52 that also has an FGFR2 gene amplification and over expression. "
08/15/2011 - "Treatment with PD173074 significantly reduced the growth of CAL51 basal-like breast cancer cell line xenografts in vivo. "
02/01/2014 - "Our studies showed that the FGFR inhibitor PD173074 decreased the viability of several human breast cancer cells, as well as 4T1 murine mammary tumor cells. "
|3.||Endometrial Neoplasms (Endometrial Cancer)
02/01/2009 - "In vitro studies have shown that endometrial cancer cell lines with activating FGFR2 mutations are selectively sensitive to a pan-FGFR inhibitor, PD173074. "
09/01/2008 - "Here, we show that shRNA knockdown of FGFR2 or treatment with a pan-FGFR inhibitor, PD173074, resulted in cell cycle arrest and induction of cell death in endometrial cancer cells with activating mutations in FGFR2. "
11/01/2012 - "In addition, although nonmutant cell lines were resistant to FGFR inhibition alone, the addition of PD173074 potentiated the cytostatic effect of paclitaxel and doxorubicin in a subset of FGFR2 wild-type endometrial cancer cell lines. "
11/01/2012 - "Human endometrial cancer cell lines with wild-type or activating FGFR2 mutations were used to determine any synergism with concurrent use of the pan-FGFR inhibitor, PD173074, and the chemotherapeutics, doxorubicin and paclitaxel, on cell proliferation and apoptosis. "
|4.||Stomach Neoplasms (Stomach Cancer)
01/01/2016 - "To investigate the mechanisms of resistance to selective FGFR inhibitors, we established three FGFR2-amplified SNU-16 gastric cancer cell lines resistant to AZD4547, BGJ398, and PD173074, respectively. "
12/01/2013 - "The aim of the present study was to explore the effects of a combination of PD173074 (PD) and 5-fluorouracil (5-Fu) on the biological behavior of gastric cancer cell lines and the relevant mechanisms involved. "
12/01/2013 - "Combination of the FGFR4 inhibitor PD173074 and 5-fluorouracil reduces proliferation and promotes apoptosis in gastric cancer."
08/01/2012 - "Further, 1 μM of foretinib or PD173074, a selective FGFR kinase inhibitor, inhibited phosphorylation of FGFR2 and downstream molecules, suggesting that foretinib targets FGFR2 in KATO-III. We confirmed this novel activity of foretinib against FGFR2 in OCUM-2M, another FGFR2-amplified gastric cancer cell line. "
|5.||Lung Neoplasms (Lung Cancer)
12/15/2010 - "Using cell-based screening with the FGFR inhibitor PD173074 in a large (n = 83) panel of lung cancer cell lines, we demonstrated that this compound inhibited growth and induced apoptosis specifically in those lung cancer cells carrying amplified FGFR1. "
10/27/2011 - "Use of an FGFR3 inhibitor (PD173074) obtained similar results with suppression of the autophosphorylation extracellular signal-regulated kinase pathway in HSC-2 cells and lung cancer cell lines. "
|4.||tyrosine receptor (receptor, tyrosine)
|6.||Small Interfering RNA (siRNA)
|7.||Fibroblast Growth Factor Receptors (Fibroblast Growth Factor Receptor)
|8.||Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor)
|9.||Protein-Tyrosine Kinases (Tyrosine Kinase)
|10.||SU 5402 (SU5402)
|1.||Heterologous Transplantation (Xenotransplantation)
|3.||Photochemotherapy (Photodynamic Therapy)